Enhancing Innovative Drug R&D through Collaborative Use of Medical Insurance Data

2025-07-01 / Read about 0 minute

Author：小编

In an effort to bolster the research and development (R&D) of innovative drugs, we aim to fortify the synergies between healthcare delivery, medical insurance, and pharmaceutical sectors. Under the strict conditions of ensuring data security, legality, and compliance, we are exploring the provision of medical insurance data services tailored for innovative drug R&D. Leveraging the national medical insurance information platform, we will delve into analyzing disease patterns and clinical medication demands, devise compatible data products, and assist pharmaceutical enterprises, scientific research institutes, and medical institutions in clarifying their R&D directions and enhancing innovation efficiency.

Previous page：CAAC Invites Public Feedback on Revised Draft of I...

Next page：Singapore Strengthens Regulations on Cryptocurrenc...

Return to List

Hot Reading

2 day ago

Banks Preparing for Aftermath of Unprecedented Catastrophe Caused by AI

2 day ago

Behind the Scenes, Meta’s Board Is Battling With Mark Zuckerberg Over His Out-of-Control AI Spending

2 day ago

We Investigated Character.AI and Found a Horror Show. Now It’s Bankrupt.

2 day ago

Forced to pick, Grok’s AI model chooses Republicans. OpenAI’s picks Democrats.